Effect of Angiotensin-Converting Enzyme Inhibition on One-Year Mortality and Frequency of Repeat Acute Myocardial Infarction in Patients With Acute Myocardial Infarction

American Journal of Cardiology

Volumn 105, Issue 9, 2010, Pages 1229-1234

  Milonas, Christos ^a   Jernberg, Tomas ^a   Lindbäck, Johan ^b   Agewall, Stefan ^a,c   Wallentin, Lars ^b   Stenestrand, Ulf ^d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^c AKER UNIVERSITY HOSPITAL   (Norway)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CALCULATION; CONTROLLED STUDY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART REINFARCTION; HISTORY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; KIDNEY DYSFUNCTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; POPULATION; PRIORITY JOURNAL; PROBABILITY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; RISK REDUCTION; SCORING SYSTEM; ST SEGMENT ELEVATION;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; SWEDEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 77950857579     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.12.032     Document Type: Article

References (28)

1. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 97 (1998) 2202-2212
2. Fourth International Study of Infarct Survival (ISIS-4) Collaborative Group. A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 345 (1995) 669-685
3. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico G. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 343 (1994) 1115-1122
4. Pfeffer M.A., Braunwald E., Moye L.A., Basta L., Brown Jr. E.J., Cuddy T.E., Davis B.R., Geltman E.M., Goldman S., Flaker G.C., and SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 327 (1992) 669-677
5. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342 (1993) 821-828
6. Kober L., Torp-Pedersen C., Carlsen J.E., Bagger H., Eliasen P., Lyngborg K., Videbaek J., Cole D.S., Auclert L., and Pauly N.C. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 333 (1995) 1670-1676
7. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G., and Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
8. Fox K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
9. Lopez-Sendon J., Swedberg K., McMurray J., Tamargo J., Maggioni A.P., Dargie H., Tendera M., Waagstein F., Kjekshus J., Lechat P., and Torp-Pedersen C. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease: the Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 25 (2004) 1454-1470
10. Bassand J.P., Hamm C.W., Ardissino D., Boersma E., Budaj A., Fernandez-Aviles F., Fox K.A., Hasdai D., Ohman E.M., Wallentin L., and Wijns W. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28 (2007) 1598-1660
11. Antman E.M., Hand M., Armstrong P.W., Bates E.R., Green L.A., Halasyamani L.K., Hochman J.S., Krumholz H.M., Lamas G.A., Mullany C.J., Pearle D.L., Sloan M.A., Smith Jr. S.C., Anbe D.T., Kushner F.G., Ornato J.P., Pearle D.L., Sloan M.A., Jacobs A.K., Adams C.D., Anderson J.L., Buller C.E., Creager M.A., Ettinger S.M., Halperin J.L., Hunt S.A., Lytle B.W., Nishimura R., Page R.L., Riegel B., Tarkington L.G., and Yancy C.W. 2007 Focused Update of the ACC/AHA2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 51 (2008) 210-247
12. Stenestrand U., and Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 285 (2001) 430-436
13. Stenestrand U., Lindback J., and Wallentin L. Anticoagulation therapy in atrial fibrillation in combination with acute myocardial infarction influences long-term outcome: a prospective cohort study from the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA). Circulation 112 (2005) 3225-3231
14. Tunstall-Pedoe H., Kuulasmaa K., Amouyel P., Arveiler D., Rajakangas A.M., and Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA project: registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 90 (1994) 583-612
15. Myocardial infarction redefined-a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 21 (2000) 1502-1513
16. D'Agostino Jr. R.B. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17 (1998) 2265-2281
17. Liu L., Zhang Y., Liu G., Li W., Zhang X., and Zanchetti A. The Felodipine Event Reduction (FEVER) study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 23 (2005) 2157-2172
18. Nissen S.E., Tuzcu E.M., Libby P., Thompson P.D., Ghali M., Garza D., Berman L., Shi H., Buebendorf E., and Topol E.J. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the Camelot study: a randomized controlled trial. JAMA 292 (2004) 2217-2225
19. Pitt B., Byington R.P., Furberg C.D., Hunninghake D.B., Mancini G.B., Miller M.E., Riley W., and PREVENT Investigators. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 102 (2000) 1503-1510
20. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002) 2981-2997
21. Shah A.D., and Arora R.R. Tissue angiotensin-converting enzyme inhibitors: are they more effective than serum angiotensin-converting enzyme inhibitors?. Clin Cardiol 28 (2005) 551-555
22. Wienbergen H., Schiele R., Gitt A.K., Juenger C., Heer T., Meisenzahl C., Landgraf H., Bossaller C., and Senges J. Impact of ramipril versus other angiotensin-converting enzyme inhibitors on outcome of unselected patients with ST-elevation acute myocardial infarction. Am J Cardiol 90 (2002) 1045-1049
23. Hansen M.L., Gislason G.H., Kober L., Schramm T.K., Folke F., Buch P., Abildstrom S.Z., Madsen M., Rasmussen S., and Torp-Pedersen C. Different angiotensin-converting enzyme inhibitors have similar clinical efficacy after myocardial infarction. Br J Clin Pharmacol 65 (2008) 217-223
24. Strippoli G.F., Bonifati C., Craig M., Navaneethan S.D., and Craig J.C. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev (2006) Oct 18:CD006257
25. Casas J.P., Chua W., Loukogeorgakis S., Vallance P., Smeeth L., Hingorani A.D., and MacAllister R.J. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366 (2005) 2026-2033
26. Gustafsson I., Torp-Pedersen C., Kober L., Gustafsson F., Hildebrandt P., and Trace Study Group. Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. J Am Coll Cardiol 34 (1999) 83-89
27. Zuanetti G., Latini R., Maggioni A.P., Franzosi M., Santoro L., and Tognoni G. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 96 (1997) 4239-4245
28. Moye L.A., Pfeffer M.A., Wun C.C., Davis B.R., Geltman E., Hayes D., Farnham D.J., Randall O.S., Dinh H., Arnold J.M., Kupersmith J., Hager D., Glasser S.P., Biddle T., Hawkins C.M., Braunwald E., and SAVE Investigators. Uniformity of captopril benefit in the SAVE study: subgroup analysis: Survival and Ventricular Enlargement study. Eur Heart J 15 Suppl B (1994) 2-8 discussion 26-30